Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Rami S. Komrokji, MD, Najla H Al Ali, Asmita Mishra, MD, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Bryan J Little, Javier Pinilla-Ibarz, MD, PhD, Jeffrey E Lancet, MD, Alan F. List, MD

Blood (2012) 120 (21): 3852.

https://doi.org/10.1182/blood.V120.21.3852.3852

Published: 2012

Journal Articles

Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes

Rami S. Komrokji, MD, Maria Corrales-Yepez, MD, Najla H Al Ali, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Javier Pinilla-Ibarz, MD, PhD, Jeffrey E Lancet, MD, Alan F. List, MD

Blood (2012) 120 (21): 3826.

https://doi.org/10.1182/blood.V120.21.3826.3826

Published: 2012

Journal Articles

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

Asmita Mishra, MD, Najla H Al Ali, Maria Corrales-Yepez, MD, Eric Padron, MD, Ling Zhang, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Mohamed A Kharfan-Dabaja, MD, Javier Pinilla-Ibarz, MD, PhD, Bryan J Little, Jeffrey E Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 2816.

https://doi.org/10.1182/blood.V120.21.2816.2816

Published: 2012

Journal Articles

GM-CSF Signaling Abnormalities in Chronic Myelomonocytic Leukemia

Eric Padron, MD, Jeffrey S. Painter, B.S., Adam W Mailloux, PhD, Jessica M. McDaniel, BS, Christopher Bebbington, DPhil., Mark Baer, PhD, Rami S. Komrokji, MD, Alan F. List, MD, Pearlie K Epling-Burnette, Pharm D, PhD

Blood (2011) 118 (21): 1713.

https://doi.org/10.1182/blood.V118.21.1713.1713

Published: 2011

Journal Articles

Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology

Lili Yang, PhD, Adam W Mailloux, PhD, Dana E Rollison, PhD, Jong Park, PhD, Jeffrey S. Painter, B.S., Rami S. Komrokji, MD, Jaroslaw P Maciejewski, MD, PhD, Ronald Paquette, MD, PhD, Thomas P. Loughran, Jr., MD, Sheng Wei, MD, Alan F. List, MD, Pearlie K Epling-Burnette, Pharm D, PhD

Blood (2011) 118 (21): 791.

https://doi.org/10.1182/blood.V118.21.791.791

Published: 2011

Journal Articles

Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes

Rami S. Komrokji, MD, Najla H Al Ali, M.S, Maria Corrales-Yepez, MD, Eric Padron, MD, Pearlie K Epling-Burnette, Pharm D, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 2777.

https://doi.org/10.1182/blood.V118.21.2777.2777

Published: 2011

NARROW

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

GM-CSF Signaling Abnormalities in Chronic Myelomonocytic Leukemia

Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology

Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities

Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes

Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.

GM-CSF Signaling Abnormalities in Chronic Myelomonocytic Leukemia

Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology

Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only